JP2020063263A5 - - Google Patents

Download PDF

Info

Publication number
JP2020063263A5
JP2020063263A5 JP2019217044A JP2019217044A JP2020063263A5 JP 2020063263 A5 JP2020063263 A5 JP 2020063263A5 JP 2019217044 A JP2019217044 A JP 2019217044A JP 2019217044 A JP2019217044 A JP 2019217044A JP 2020063263 A5 JP2020063263 A5 JP 2020063263A5
Authority
JP
Japan
Prior art keywords
hematopoietic stem
cells
pge
activity
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019217044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020063263A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020063263A publication Critical patent/JP2020063263A/ja
Publication of JP2020063263A5 publication Critical patent/JP2020063263A5/ja
Priority to JP2023001015A priority Critical patent/JP2023052244A/ja
Withdrawn legal-status Critical Current

Links

JP2019217044A 2008-11-06 2019-11-29 造血幹細胞の生着手順を強化するための材料および方法 Withdrawn JP2020063263A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023001015A JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11201808P 2008-11-06 2008-11-06
US61/112,018 2008-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017195168A Division JP2018048156A (ja) 2008-11-06 2017-10-05 造血幹細胞の生着手順を強化するための材料および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023001015A Division JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Publications (2)

Publication Number Publication Date
JP2020063263A JP2020063263A (ja) 2020-04-23
JP2020063263A5 true JP2020063263A5 (cg-RX-API-DMAC7.html) 2020-09-03

Family

ID=42153284

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011534934A Expired - Fee Related JP5846915B2 (ja) 2008-11-06 2009-11-06 造血幹細胞の生着手順を強化するための材料および方法
JP2015134076A Expired - Fee Related JP6632822B2 (ja) 2008-11-06 2015-07-03 造血幹細胞の生着手順を強化するための材料および方法
JP2017195168A Withdrawn JP2018048156A (ja) 2008-11-06 2017-10-05 造血幹細胞の生着手順を強化するための材料および方法
JP2019217044A Withdrawn JP2020063263A (ja) 2008-11-06 2019-11-29 造血幹細胞の生着手順を強化するための材料および方法
JP2023001015A Pending JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2011534934A Expired - Fee Related JP5846915B2 (ja) 2008-11-06 2009-11-06 造血幹細胞の生着手順を強化するための材料および方法
JP2015134076A Expired - Fee Related JP6632822B2 (ja) 2008-11-06 2015-07-03 造血幹細胞の生着手順を強化するための材料および方法
JP2017195168A Withdrawn JP2018048156A (ja) 2008-11-06 2017-10-05 造血幹細胞の生着手順を強化するための材料および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023001015A Pending JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Country Status (10)

Country Link
US (5) US9107909B2 (cg-RX-API-DMAC7.html)
EP (3) EP3031907B1 (cg-RX-API-DMAC7.html)
JP (5) JP5846915B2 (cg-RX-API-DMAC7.html)
CN (4) CN102245758A (cg-RX-API-DMAC7.html)
AU (4) AU2009313290B2 (cg-RX-API-DMAC7.html)
CA (3) CA3203374A1 (cg-RX-API-DMAC7.html)
ES (1) ES2845641T3 (cg-RX-API-DMAC7.html)
PT (1) PT3031907T (cg-RX-API-DMAC7.html)
WO (1) WO2010054271A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804932B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
CN103167876B (zh) * 2010-08-12 2016-08-31 菲特治疗公司 改进的造血干细胞和祖细胞疗法
PL2663313T3 (pl) * 2011-01-13 2019-01-31 SciPharm S.à r.l. Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
WO2013130499A1 (en) * 2012-02-29 2013-09-06 University Of Virginia Patent Foundation Compositions and methods for cxcr4 signaling and umbilical cord blood stem cell engraftment
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
JP6285930B2 (ja) * 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ,インク. 造血コンパートメントの再構築及び自家再構築の増進
US20150216903A1 (en) * 2012-08-10 2015-08-06 Bluebird Bio, Inc. Compounds for improved viral transduction
WO2014134539A1 (en) 2013-02-28 2014-09-04 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP4091609A1 (en) 2013-04-29 2022-11-23 Medregen, LLC Wound healing via autologous stem cell mobilization
KR101489861B1 (ko) * 2013-05-07 2015-02-05 경북대학교 산학협력단 Amd3100을 포함하는 골질환 예방 또는 치료용 조성물
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CN104774806B (zh) * 2015-04-09 2019-02-15 广州赛莱拉干细胞科技股份有限公司 一种胎盘造血干细胞的制备方法
BR112018001232A2 (pt) 2015-07-21 2018-09-25 The Children's Medical Center Corporation pd-l1 que expressa células-tronco hematopoéticas e usos
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
KR20250134722A (ko) 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
WO2017147610A1 (en) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
US20200224165A1 (en) * 2016-07-22 2020-07-16 Senlin Li Methods and compositions for rejuvenation
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
AU2018212854B2 (en) 2017-01-27 2024-06-20 Children's Hospital Medical Center Methods of enhancing engraftment activity of hematopoietic stem cells
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11213546B2 (en) 2017-09-07 2022-01-04 Emory University Methods to mobilize tissue resident cells for adoptive t cell therapy
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
CN108404112B (zh) * 2018-04-01 2020-05-12 北京诺赛启研再生医学研究院有限公司 提高造血干细胞归巢及植入率的方法及其试剂
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
EP3952909A4 (en) 2019-04-08 2023-06-07 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS
SG11202112529WA (en) 2019-05-14 2021-12-30 Taiga Biotechnologies Inc Compositions and methods for treating t cell exhaustion
JP7543395B2 (ja) 2020-03-31 2024-09-02 デンカ株式会社 アルミナ粉末、樹脂組成物、及び放熱部品
CN116509834B (zh) * 2023-01-20 2025-05-13 东北师范大学 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
CA2462628C (en) * 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
EP1461087A1 (en) * 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
EP1471818A4 (en) * 2002-02-04 2007-03-28 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
JP4865541B2 (ja) 2003-04-08 2012-02-01 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 化学誘引物質に対する増大させた感受性を有する幹細胞およびそれを産生および使用する方法
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2006001463A1 (ja) * 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. S1p受容体結合能を有する化合物およびその用途
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2007041511A2 (en) * 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
JP2007099724A (ja) 2005-10-06 2007-04-19 Shizuoka Prefecture スルファチドを標的とした抗ウイルス剤
US8076315B2 (en) * 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
EP1999255A2 (en) * 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2007148332A1 (en) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Catecholamine receptor modulation
EP3824885A1 (en) 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
US8598328B2 (en) 2006-12-13 2013-12-03 National University Corporation Nagoya University Tol1 factor transposase and DNA introduction system using the same
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction

Similar Documents

Publication Publication Date Title
ES2401608T3 (es) Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes
MY197586A (en) Adenovirus armed with bispecific t cell engager (bite)
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
CO2021006362A2 (es) Construcciones de ácido nucleico y métodos de uso
ES2900560T3 (es) Terapia génica.
JP2018184448A5 (cg-RX-API-DMAC7.html)
MX2025013445A (es) Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado
MY209906A (en) Lipid nanoparticle formulations of non-viral, capsid-free dna vectors
MX2021001292A (es) Metodos para la modificacion genica de celulas hematopoyeticas.
MX2022010363A (es) Formulaciones clinicas.
MX2024012761A (es) Terapia genica con el atanogeno 3 asociado a linfoma de celulas b 2 (bag3) utilizando el vector aav
MX2020005663A (es) Terapia genica para mucopolisacaridosis iii a.
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
Zhou et al. IFNα‐expressing amniotic fluid‐derived mesenchymal stem cells migrate to and suppress HeLa cell‐derived tumors in a mouse model
Petersen et al. Efficient transduction of equine adipose-derived mesenchymal stem cells by VSV-G pseudotyped lentiviral vectors
JP2019068814A5 (cg-RX-API-DMAC7.html)
Perlea et al. Phenotype heterogeneity in dental pulp stem niches
CA3217059A1 (en) Compositions for improving the transduction of cells by viral vectors
Yusoff et al. A comparison of culture characteristics between human amniotic mesenchymal stem cells and dental stem cells
Aizenshtadt et al. Charachterization of umbilical cord mesenchymal stromal cells during long-term expansion in vitro
ATE481495T1 (de) Adenovirusvektor
Hoetzenecker Step by step toward the summit
George et al. Editing of highly homologous gamma-globin genes by nickase deficient Base Editor mitigates large intergenic deletions
Nicholson et al. 118. Inhibition of Hepatitis B Virus Replication In Vivo Following Delivery of Antiviral TALENs With Recombinant Adeno-Associated Viral Vectors
MY190213A (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues